Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population.
Hered Cancer Clin Pract
; 19(1): 6, 2021 Jan 08.
Article
em En
| MEDLINE
| ID: mdl-33419454
ABSTRACT
INTRODUCTION:
The role of PALB2 in carcinogenesis remains to be clarified. Our main goal was to determine the prevalence of PALB2 (509_510delGA and 172_175delTTGT) mutations in bladder and kidney cancer patients from Polish population. MATERIALS ANDMETHODS:
1413 patients with bladder and 810 cases with kidney cancer and 4702 controls were genotyped for two PALB2 variants 509_510delGA and 172_175delTTGT.RESULTS:
Two mutations of PALB2 gene were detected in 5 of 1413 (0.35%) unselected bladder cases and in 10 of 4702 controls (odds ratio [OR], 1.7; 95% CI 0.56-4.88; p = 0.52). Among 810 unselected kidney cancer cases two PALB2 mutations were reported in two patients (0,24%) (odds ratio [OR], (OR = 1.2; 95% CI 0.25-5.13; p = 0.84). In cases with mutations in PALB2 gene cancer family history was negative.CONCLUSION:
We found no difference in the prevalence of recurrent PALB2 mutations between cases and healthy controls. The mutations in PALB2 gene seem not to play a major role in bladder and kidney cancer development in Polish patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article